UK-based Macomics Ltd has invited Valérie Méresse Naegelen of Roche to join a clinical advisory panel that will assist it develop new medicines for cancer. The company’s technology targets disease specific tumour associated macrophages, a type of white blood cell that kills microorganisms. At Roche, Dr Naegelen oversees translational and clinical activities related to the in-licensing and acquisition of assets. She has experience in early and late clinical stage development of treatments for both solid tumours and haematological diseases. The new panel also includes eight other advisors from five European countries.
Macomics announced the appointment on 12 September 2022.
Copyright 2022 Evernow Publishing Ltd